Laura Alder, MD

Live from TTLC25: Lung Cancer and Brain Metastasis | IASLC In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses lung cancer and brain metastasis with Dr. Laura Alder.

Did you catch the most recent episode of #LungCancerConsidered? @narjustflorezmd.bsky.social & @lauraaldermd.bsky.social dive into lung cancer & brain metastases—why MRI surveillance matters, how to time radiation & balancing risks like radiation necrosis.

🎧 Listen now: bit.ly/TTLC25LC-BM

Mentorship meeting with Dr. @LauraAlderMD in Miami… I can get used to this

Aims 1, 2, and 3 drafted

Up to next !

2025 @precisca Fellows Retreat

ABC11 Together Perspectives for March: Durham Crop Hunger Walk and Walk to Defeat Dementia ABC11 Together Perspectives for March includes fundraiser for lung cancer research

Check out the ABC11 interview with @lauraaldermd.bsky.social, our Deputy Medical Director, about lung cancer, new treatments, and the Duke Center for Brain and Spine Metastasis. (Her interview starts at the 4-minute mark!)

abc11.com/post/abc11-t...

Muck Rack | For journalists and public relations Use Muck Rack to find journalists, get press for your story, monitor the news and report on the impact of your PR. Journalists can build portfolios and accelerate their careers.

Honored to discuss lung cancer with ABC11 highlighting screening, self-advocacy, destigmatization, and the crucial impact of research on cancer treatments resulting in improved QoL and outcomes. @dukecancer.bsky.social #LCSM #LungCancer #CancerResearch #OncSky

muckrack.com/broadcast/sa...

A Lancet Editorial: “American chaos: standing up for health and medicine”

“...to care is an act not of weakness, but of strength.”

The Lancet response: bit.ly/4jRb5Av

So honored, thankful, and excited to be a part of the 2025 IASLC Academy. Can’t wait to meet the cohort and the mentors, form new connections and collaborations, and learn from such stellar minds!!

@iaslc.bsky.social #LCSM

Always enjoy these JTO "Controversies in Thoracic Oncology!" This issue's relevant debate of including adjuvant IO after neo-adj chemo/IO raises great points, reviews current data, highlights the unknown.
@drcamidge.bsky.social #LCSM

www.jto.org/article/S155...

www.jto.org/article/S155...

Excellent review of lung neuroendocrine neoplasms by Dr Sen,
@naglaakarimmd.bsky.social and team! Terrific discussion of molecular landscape, existing therapeutic challenges, and diagnosis & management strategies.
#LCSM #LungNETs #SCLC
@thelancet.bsky.social

www.thelancet.com/journals/lan...

Treating Second-Line NSCLC: The Efficacy of ADCs Targeting Predictive Biomarkers The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and ...

Was happy to talk about the current status of NSCLC ADC's after WCLC24! Looking forward to more advances in 2025! #lcsm #oncsky

Important study and data in a patient group lacking strong next line options. Additionally notable with suggestion of CNS efficacy.

Also looking forward to approval and additional data on promising Patritumab Deruxtecan (HER3-DXd) in such a setting

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA

1. #Tepotinib
2. #Osimertinib x2
3. #Alectinib
4. #Tarlatamab
5. #Zenocutuzumab
6. #Durvalumab x2
7. #Amivantamab x2
8. #Nivolumab (now SubQ)
9. #Ensartinib

#lcsm #OncSky #MedSky #Cancer

“The Lemon Tree” was a great read!

Decoding the Clinical and Molecular Signatures of EGFR Common, Compound, and Uncommon Mutations in Non-Small Cell Lung Cancer. Epidermal growth factor receptor (EGFR) mutations are key oncogenic drivers in lung adenocarcinoma (LUAD), predominantly affecting Asian, non-smoking, and female populations. While common mutations, such as exon 19 deletions and L858R, respond well to tyrosine kinase inhibitors (TKIs), uncommon EGFR mutations and compound variants exhibit variable treatment responses. This study aims to compare clinical characteristics and molecular profiles of patients with common, uncommon, and compound EGFR mutations, assessing their implications for therapy outcomes.

Details on uncommon #EGFR mutations @jtoonline.bsky.social. In 5212 #EGFR NSCLC dataset, 8.9% were uncommon mutations: associated with smoking history, higher rates of EGFR amp and TP53 co-mt, shorter time on TKI (4.1m) vs common (10.9m). #LCSM #OncSky

www.jto.org/article/S155...

Thoughtful commentary on perioperative immunotherapy for NSCLC from Drs. Tina Cascone and William William in Nature Reviews Clinical Oncology with their editorial on long-term data, durable benefit, and unanswered questions from the NADIM trial. #LCSM #OncSky

www.nature.com/articles/s41...

So honored to be named Deputy Director of Duke Center for Brain and Spine Mets! CNS Mets in #lcsm is an area I’m passionate about, eager to collaborate with friends here #oncsky and continue to advance the field forward!!
@dukemedschool.bsky.social @dukeneurosurgery.bsky.social

We have known for decade+ that you can detect progression using ctDNA months before you see it on scans. But until we show that it impacts outcomes to change tx earlier all it does is make ppl anxious and abandon treatments (TKIs) that may still be helping. Most MRD use today is marketing over data.

Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with limited-stage small cell lung cancer.

Durvalumab now FDA approved for limited stage #SCLC based on the phase III ADRIATIC trial showing a PFS and an OS benefit (HR 0.73) with 2y of durvalumab after completion of definitive chemoradiation (avoid concurrent use). #LCSM #OncSky

www.targetedonc.com/view/durvalu....

a man with ice on his face is standing in the snow with the word hdad in the corner ALT: a man with ice on his face is standing in the snow with the word hdad in the corner

What freezings I have felt, what dark days seen,
What old December's bareness everywhere!
-Sonnet 97

#Frozen #ShakespeareSunday

A must-read Review on the ever-evolving field of #EGFR mut #NSCLC in @natrevclinoncol.bsky.social highlighting:

➡️Strategies to improve on 1L 3rd Gen TKI mono therapy

➡️ Ways to tackle resistance post-Osi
➡️Perioperative landscape

@LeXiuning @danieltanmd @RamalingamMD @IASLC

#LCSM #some

Lung cancer research and treatment: global perspectives and strategic calls to action Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to r…

Great summary in @Annals_Oncology of an intensive few days in March 2024 discuss the key issues confronting lung cancer care globally, thanks to Dr. @mayluciemeyer for her excellent leadership on this manuscript! #lcsm @IASLC @myESMO
www.sciencedirect.com/science/arti...

Surgical resectability for locally advanced #LungCancer redefined -

Explore our expert consensus on who is eligible for curative #surgery in the age of #immunotherapy and targeted treatments.

From STS
#LCSM #SurgSky #MedSky #CancerSky

www.annalsthoracicsurgery.org/article/S000...

Using tumor DNA methylomes to predict cancer metastasis to the brain - Nature Medicine Metastatic spread of cancer to the brain has a devastating effect on patient outcomes, yet identifying patients who will develop brain metastases is difficult in current clinical practice. We show tha...

Intriguing paper utilizing unique DNA methylation signatures of LUAD brain metastases to predict risk and aid in noninvasive diagnosis via plasma. Many applications if prospectively validated: surveillance imaging timepoints, optimal treatment selection and timing.

www.nature.com/articles/s41...

Promising results in a patient population in huge need of improved treatment options and outcomes! Eager to see additional results #lcsm #oncsky

“Receptor Gadget” 🕵️‍♂️

Add me, please! Thank you!

76% 5 year OS, even with small numbers, represents such magnificent accomplishments in #LCSM! Taken with CROWN data (5 year PFS 60%, 92% pts free from intracranial progression!) helps cement Lorlatinib as clear 1st line choice for metastatic #lungcancer #oncsky @alkpositiveuk.bsky.social

Please add me!

Rising lung cancer cases in nonsmoking women under 50: Experts urge awareness An unexpected surge in lung cancer cases among nonsmoking women under 50 is raising alarms among oncologists, emphasizing the need for heightened awareness.

Honored to be interviewed about the rising incidence of lung cancer in non-smokers and especially females on @wral.bsky.social to shed light on #LCSM during #LungCancerAwarenessMonth and highlight the #HearHer campaign

www.wral.com/lifestyle/he...

@younglungcancer.bsky.social

Nice to see these guidelines on differentiating two primary lesions from metastatic disease in patients with NSCLC, an occasional diagnostic challenge. Big advance in past decade is using NGS www.jto.org/article/S155...

Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update | Journal of Clinical Oncology ASCO Rapid Recommendation Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an e...

Working on the #ASCO #SCLC guidelines, published in 2023, was disheartening, but working on the rapid update (based on #ASCO24 data) left me emotional.
This update represents hope & progress for patients who have waited far too long. ascopubs.org/doi/10.1200/...
#LCSM